Skip to main content
Clinical Trials/NCT03458988
NCT03458988
Completed
Not Applicable

Pilot Study to Validate a Novel Blood-pressure Measuring Device in Patients Carrying a Left Ventricular Assist Device

Insel Gruppe AG, University Hospital Bern1 site in 1 country30 target enrollmentFebruary 27, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Left Ventricular Assist Device
Sponsor
Insel Gruppe AG, University Hospital Bern
Enrollment
30
Locations
1
Primary Endpoint
RR (Riva Rocci, indirect blood pressure measurement) in LVAD
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

To prove the novel device is able to reliably detect pulsatility in patients with CF-VADs and to analyze whether pre-programmed intrinsic pulsatility of the 3rd generation CF-VADs can also be picked up. The study is not designed to measure blood pressure.

Should this pilot study be successful in detecting enough pulsatility a follow-up study would then try to transfer the results into blood-pressure values with the help of comparators in order to identify an easier and more reliable method to measure BP in CF-VAD patients. .

Detailed Description

The number of patients supported by left ventricular assist device (LVAD) is increasing as durable mechanical support has become widely available for end stage heart failure as destination therapy and as bridge to transplantation. The accurate measurement of blood pressure (BP) as well as the recognition and management of hypertension in patients with LVADs is an essential component of optimal clinical care. Hypertension is an established long-term risk factor for cardiovascular disease. The measurement of BP and the management of hypertension in patients with CF-VADs can present unique challenges. Patients with LVADs often do not have a palpable pulse, and therefore traditional BP measurement by auscultation or automated cuff is less reliable. Conventional occlusive BP measurement is able to to pick up signals in approximately 50% of cases due to coincidental phases of pulsatility. The arterial line is the gold standard, but is an invasive procedure and not practical for routine outpatient use. Although efforts are underway to identify an easier and more reliable method to measure ambulatory BP in these patients not one has been able to match the quality of an invasive arterial line.

Registry
clinicaltrials.gov
Start Date
February 27, 2018
End Date
December 31, 2020
Last Updated
4 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients carrying one of the two third generation CF-VADS (Heartware HVAD, Heartmate 3)
  • Patients \>18y
  • Good understanding of written and oral German
  • Signed informed consent
  • Scheduled for routine outpatient appointment.

Exclusion Criteria

  • In the population of the outpatient clinic's CV-LVAD patients no known exclusion criteria exists

Outcomes

Primary Outcomes

RR (Riva Rocci, indirect blood pressure measurement) in LVAD

Time Frame: 10 min blood measuring

Detect pulsatility in CF-VAD (Continuous flow- ventricular assist device) patients sufficient to calculate comprehensible blood-pressure values in future follow-up studies

Study Sites (1)

Loading locations...

Similar Trials